US Patent

US11065224 — Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Formulation · Assigned to Flamel Ireland Ltd · Expires 2037-07-21 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties.

USPTO Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Drugs covered by this patent

sodium-oxybate (SODIUM OXYBATE)

Patent Metadata

Patent number: US11065224
Jurisdiction: US
Classification: Formulation
Expires: 2037-07-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Flamel Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.